Jols 100billion-won capital increase; Kosdaq funding disclosures continued
Jols 99billion 9999million 9240won third-party 3allotment paid-in capital increase. Cytogen disclosed 52 billion won in convertible bonds, while AutoHands applied for a preliminary review for a Kosdaq listing.
Get free 졸스 email updates.
Bullstory sends one daily email when new analysis or important company news is available.

Kosdaq-listed Jols 2026 year 5 month 18 day, decided on a third-party 3allotment paid-in capital increase, the company disclosed. The amount to be raised is 99 billion 9999 million 9240 won. The company said it would raise funds for operating capital and other purposes.
This paid-in capital increase allocates new shares to specific recipients. Jols said it would issue the new shares as common stock. The purpose of the fundraising includes securing funds needed to operate the company.
Cytogen disclosed the issuance of convertible bonds on the same day. The issue size is 52 billion won. These corporate bonds can be converted into shares under specified terms.
Cytogen’s conversion price is 5,445 won. The conversion request period begins on 2027 of 5 and starts on 26. After that, investors can convert the bonds into shares under the specified terms.
Korea Union Pharmaceutical also announced that it had decided on a 3 paid-in capital increase through an allocation to designated parties. In one disclosure, Bukwang Pharmaceutical Co., Ltd. was named as an allottee. In another disclosure, Park Gwang-seok and others were listed as allottees.
Autohands filed an application for a preliminary KOSDAQ listing review. The KOSDAQ Market Division of the Korea Exchange said it had received the application on 2026 of 5 and 18. Autohands operates in automobile sales.
The day's disclosures and filing came amid fundraising by KOSDAQ-listed companies and preparations for new listings. JOLSE and Korea Union Pharmaceutical are issuing new shares. Cytogen is issuing convertible bonds.